Western Blot: Park7/DJ-1 Antibody [NB100-1194] - Human Cerebellum (A), Human Frontal Cortex (B), Human Hippocampus (C) Mouse Fetal Brain (D), Mouse Brain (E) and Rat Brain (F) lysates (35 ug protein in RIPA buffer). ...read more
Western Blot: Park7/DJ-1 Antibody [NB100-1194] - HeLa (A) and Jurkat (B) lysates (35 ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
WB: Approx. 24 kDa band observed in HeLa and Jurkat lysates and of human brain (cerebellum, hippocampus, frontal cortex) and rodent brain lysates (calculated MW of 19.9 kDa band according to NP_001116849.1 and of NP_009193.2).
The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
20 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read 1 Review rated 3 using NB100-1194 in the following applications:
Parkinson disease (autosomal recessive, early onset) 7
Parkinson disease protein 7
PARK7/DJ1 is a ubiquitously expressed protein involved in various cellular processes including cell proliferation, RNA-binding, and oxidative stress. The protein has been found to colocalize within a subset of pathologic tau inclusions in a diverse group of neurodegenerative disorders known as tauopathies (Rizzu et al. 2004). Defects in PARK7/DJ1 are the cause of autosomal recessive early-onset Parkinson's disease 7 (PARK7). Parkinson's disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years. The disease is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK7 is characterized by onset before 40 years and slow progression. It has also been suggested that PARK7/DJ1 is a mitogen dependent oncogene product involved in Ras related signal transduction pathways.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.